Dear Editor,
Few substances embody medical duality as starkly as botulinum toxin (BoNT), a molecule capable of killing with a single nanogram, yet trusted by millions to smooth wrinkles, silence migraines, and restore function. Once feared as a bioweapon, BoNT now stands as a pillar of modern therapeutics. However, with great power comes great responsibility and risk. This editorial argues that while BoNT’s clinical expansion is remarkable, its dual-use nature demands stricter oversight, smarter delivery systems, and global coordination to prevent misuse without stifling innovation. Clostridium botulinum primarily produces BoNTs; this anaerobic, spore-forming, gram-positive bacterium, along with related species including C. butyricum, C. baratii, and C. argentinensis, synthesizes various toxin forms (1, 2). The BoNT is one of the most poisonous biological substances known, which appears in the environment, frequently in the form of spores, and causes several clinical syndromes known as botulism, characterized by paralysis, respiratory failure, and, if untreated, death (3, 4). This syndrome occurs after eating contaminated food, wound infection, or colonization of the infant’s gut (5). The BoNT molecular mechanism of action involves the intracellular blocking of the acetylcholine release at nerve terminals, leading to disruption of the neurotransmission and progressive paralysis (6). Researchers estimate that the human median lethal dose (LD50) for botulism is 1 to 3 nanograms per kilogram of body mass, making it one of the most lethal substances worldwide (7). Because of its high toxicity, lethality, and possible application as a biological weapon, the Centers for Disease Control and Prevention (CDC) classifies BoNT as a category A agent (8).
Despite its toxicity, clinicians and researchers increasingly use BoNTs in modern medicine across various fields, including urology, dermatology, cosmetic medicine, neurology, pain management, oncology, and psychiatry, with a broader range of clinical applications than any other available pharmacological drugs (9). Medically controlled doses of BoNT formulations treat various disorders, including cervical dystonia, blepharospasm, hemifacial spasm, focal spasticity, chronic migraine, overactive bladder, excessive sweating, and cosmetic issues such as vertical and horizontal frown lines and crow’s feet. Researchers also investigate its potential for painful keloids, diabetic neuropathic pain, trigeminal neuralgia, scarring, cancer, and depression (10-12). The therapeutic mechanism of BoNT is based on the same neuromuscular blocking effect that makes the toxin extremely dangerous; however, under close medical supervision, clinicians have transformed BoNT from a lethal neurotoxin into a highly therapeutic agent with wide-ranging clinical applications (13).
In therapeutic doses, clinicians consider BoNT generally safe with relatively few self-limited negative effects, including muscle weakness, extreme tiredness, dizziness, oral dryness, flu-like illness, and a skin rash (14, 15). Serious complications are rare but possible, including neurological problems, spread to non-target muscles, anaphylactic reactions, and other adverse events; therefore, prescribers must recognize its potential risks (16, 17). Furthermore, the development of neutralizing antibodies (NAbs), effective antitoxins, new delivery systems (such as nanoparticles), and vaccines [including the tetravalent botulinum vaccine (TBV)] plays a critical role in reducing the potential risks associated with clinical use and accidental or intentional exposure (18-22).
Future research on BoNT should prioritize innovations that enhance its therapeutic precision, safety, and duration of action. Advances in biotechnology — such as nanocarriers, targeted delivery systems, and engineered BoNT variants — offer promising strategies to optimize its medical potential while minimizing risks of misuse. To harness BoNT’s full potential while minimizing risk, we urge: (1) Standardized global surveillance for antibody development, (2) investment in targeted delivery platforms to reduce off-target effects, and (3) the establishment of ethical frameworks for emerging psychiatric and oncological applications. Such coordinated action will ensure BoNT’s continued evolution as both a powerful and responsibly managed therapeutic tool for future medicine.
